Linked Life Data

15090739

Source:http://linkedlifedata.com/resource/pubmed/id/15090739

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2004-4-19
pubmed:abstractText
Our objective was to evaluate the activity and safety of the combination of cisplatin, epirubicin and vinorelbine (CEV) in advanced breast cancer patients. Patients with advanced breast cancer, locally advanced or metastatic, received epirubicin 75 mg/m2 and cisplatin 50 mg/m2 on day 1, and vinorelbine 25 mg/m2 on day 8. Cycles were repeated every 3 weeks. A total of 35 patients were treated. Thirty-one patients were evaluated for response. One hundred and fifty-five cycles of chemotherapy were administered overall. The objective response rate (ORR) was 84%, including complete response in 13% of patients. All stage III patients achieved a downstaging, with a pathological complete response in two out of 10 patients. Patients with stage IV disease obtained objective response in 67% of cases. Toxicity was mild to moderate. The most common grade 3-4 adverse event was febrile neutropenia, which occurred in 17% of patients. We conclude that CEV combination represents an effective treatment for patients with previously untreated advanced breast cancer, allowing an important ORR. Moreover this regimen appears to be well tolerated.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
0959-4973
pubmed:author
pubmed:issnType
Print
pubmed:volume
15
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
23-7
pubmed:dateRevised
2006-4-24
pubmed:meshHeading
pubmed:year
2004
pubmed:articleTitle
A phase II study of epirubicin, vinorelbine and cisplatin in advanced breast cancer.
pubmed:affiliation
Divisions of Medical Oncology, S. Croce General Hospital, Cuneo, Italy. ornella.garrone@tiscali.it
pubmed:publicationType
Journal Article, Clinical Trial, Clinical Trial, Phase II